Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis

被引:5
|
作者
Zhang, Liulu [1 ]
Chen, Yuanqi [1 ,2 ]
Cheng, Min-Yi [1 ]
Zhuang, Xiaosheng [3 ]
Zou, Jiachen [1 ]
Wei, Dannuo [4 ]
Lin, Ying-Yi [1 ]
Zhang, Yi [1 ]
Wang, Kun [1 ]
机构
[1] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Breast Canc, Ctr Canc, 106 Zhongshan Er Rd, Guangzhou 510080, Peoples R China
[2] Southern Med Univ, Sch Clin Med 2, Guangzhou, Peoples R China
[3] Chinese Univ Hong Kong, Sch Life Sci, Dept Cell & Mol Biol, Shatin, Hong Kong, Peoples R China
[4] Univ Hong Kong, Dept Social Work & Social Adm, Pokfulam, Hong Kong, Peoples R China
基金
中国国家自然科学基金;
关键词
homologous recombination deficiency; platinum-based chemotherapy; triple-negative breast cancer; PATHOLOGICAL COMPLETE RESPONSE; PHASE-II; CARBOPLATIN; DOXORUBICIN; CYCLOPHOSPHAMIDE; GEMCITABINE; SENSITIVITY; GEPARSIXTO; CISPLATIN; REPAIR;
D O I
10.1177/17588359221096253
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Recent studies have shown that homologous recombination deficiency (HRD) may be correlated with the pathological complete response (pCR) rate. This meta-analysis aimed to determine the predictive value of HRD for the pCR rate in patients with triple-negative breast cancer (TNBC) receiving platinum-based neoadjuvant chemotherapy (NCT). Methods: Published articles were searched in the PubMed, Embase, Medline, Web of Science, and Cochrane databases up to 1 June 2021, and studies reporting the pCR rate for HRD carriers on platinum-based NCT were selected. Odds ratios (ORs) with 95% confidence intervals (CIs) were determined for the pCR rate, clinical response rate, and Grade 3 or higher adverse events (AEs) using the random-effects model. Bias risk was evaluated using the Cochrane Collaboration tool (PROSPERO, registration number CRD42021249874). Results: Seven studies were eligible. The results showed that HRD carriers had higher pCR rates than non-HRD carriers across all treatment arms (OR = 3.84, 95% CI = [1.93, 7.64], p = 0.0001). Among HRD carriers, the pCR rate was higher in patients on platinum-based NCT than in those without platinum exposure (OR = 1.95, 95% CI = [1.17, 3.23], p = 0.01). We did not observe marked pCR improvements in non-HRD carriers. Among HRD carriers, the pCR rates in the mutant and wild-type breast cancer susceptibility gene (BRCA) groups did not differ significantly (OR = 2.00, 95% CI = [0.77, 5.23], p = 0.16), but HRD carriers with wild-type BRCA had a significant advantage over non-HRD carriers on platinum-based NCT (OR = 3.64, 95% CI = [1.83, 7.21], p = 0.0002). Conclusion: HRD is an effective predictor of increased pCR rates in platinum-based NCT, especially in wild-type BRCA patients. Adding platinum to NCT for non-HRD carriers can increase the incidence of AEs but may not improve the therapeutic effect.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in patients with early-stage triple-negative breast cancer: A meta-analysis
    Chen, Yuanqi
    Zhang, Liulu
    Cheng, Minyi
    Zhuang, Xiaosheng
    Yang, Ci-Qiu
    Ji, Fei
    Gao, Hong-Fei
    Yang, Mei
    Zhu, Teng
    Li, Jieqing
    Wang, Kun
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [2] Homologous recombination deficiency predicts response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: Secondary analysis of the neocart randomized clinical trial.
    Zhang, Liulu
    Wu, Zhiyong
    Li, Jie
    Lin, Ying
    Liu, Zhenzhen
    Cao, Yin
    Zhang, Gangling
    Zhang, Yi
    Chen, Yuanqi
    Gao, Hong-Fei
    Yang, Mei
    Yang, Ciqiu
    Zhu, Teng
    Cheng, Min-Yi
    Ji, Fei
    Li, Jieqing
    Wang, Kun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis
    Li, Zhen-Yu
    Zhang, Zhen
    Cao, Xiao-Zhong
    Feng, Yun
    Ren, Sha-Sha
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2020, 48 (10)
  • [4] Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
    Poggio, F.
    Bruzzone, M.
    Ceppi, M.
    Ponde, N. F.
    La Valle, G.
    Del Mastro, L.
    de Azambuja, E.
    Lambertini, M.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (07) : 1497 - 1508
  • [5] Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis
    Chai, Yue
    Chen, Yujie
    Zhang, Di
    Wei, Yuce
    Li, Zhijun
    Li, Qiao
    Xu, Binghe
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (02):
  • [6] Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis
    Saleh, Ramy R.
    Nadler, Michelle B.
    Desnoyers, Alexandra
    Meti, Nicholas
    Fazelzad, Rouhi
    Amir, Eitan
    [J]. CANCER TREATMENT REVIEWS, 2021, 100
  • [7] Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis
    Saleh, Ramy
    Nadler, Michelle B.
    Desnoyers, Alexandra
    Fazelzad, Rouhi
    Amir, Eitan
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [8] Platinum-based chemotherapy for early triple-negative breast cancer: A Cochrane systematic review and meta-analysis
    Mason, Sofia
    Willson, Melina
    Goodwin, Annabel
    Beith, Jane
    Egger, Sam J.
    Dear, Rachel F.
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [9] Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis
    Zhao, Fuxing
    Shen, Guoshuang
    Dong, Qiuxia
    Xin, Yuanfang
    Huo, Xingfa
    Wang, Miaozhou
    Liu, Zhen
    Zhao, Yi
    Ren, Dengfeng
    Xie, Qiqi
    Liu, Zhilin
    Li, Zitao
    Gao, Lihong
    Du, Feng
    Zhao, Jiuda
    [J]. CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (06) : 2025 - 2040
  • [10] Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis
    Fuxing Zhao
    Guoshuang Shen
    Qiuxia Dong
    Yuanfang Xin
    Xingfa Huo
    Miaozhou Wang
    Zhen Liu
    Yi Zhao
    Dengfeng Ren
    Qiqi Xie
    Zhilin Liu
    Zitao Li
    Lihong Gao
    Feng Du
    Jiuda Zhao
    [J]. Clinical and Experimental Medicine, 2023, 23 : 2025 - 2040